Sandra Demaria
Overview
Explore the profile of Sandra Demaria including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
160
Citations
16092
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen J, Levy A, Tian A, Huang X, Cai G, Fidelle M, et al.
Cancer Cell
. 2025 Mar;
43(3):361-379.e10.
PMID: 40068595
The mechanisms governing the abscopal effects of local radiotherapy in cancer patients remain an open conundrum. Here, we show that off-target intestinal low-dose irradiation (ILDR) increases the clinical benefits of...
2.
Morris Z, Demaria S, Monjazeb A, Formenti S, Weichselbaum R, Welsh J, et al.
Lancet Oncol
. 2025 Mar;
26(3):e152-e170.
PMID: 40049206
Radiotherapy both promotes and antagonises tumour immune recognition. Some clinical studies show improved patient outcomes when immunotherapies are integrated with radiotherapy. Safe, greater than additive, clinical response to the combination...
3.
Laurent P, Andre F, Bobard A, Deandreis D, Demaria S, Depil S, et al.
Oncoimmunology
. 2024 Dec;
14(1):2432726.
PMID: 39696783
Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring...
4.
Buque A, Bloy N, Petroni G, Jimenez-Cortegana C, Sato A, Iribarren C, et al.
J Natl Cancer Inst
. 2024 Dec;
PMID: 39661487
Background: Hormone receptor (HR)+ breast cancer is poorly responsive to immune checkpoint inhibitors (ICIs). In some settings, radiation therapy (RT) has been shown to mediate immunostimulatory effects and promote ICI...
5.
Charpentier M, Bloy N, Formenti S, Galluzzi L, Demaria S
J Vis Exp
. 2024 Apr;
(206).
PMID: 38647326
Radiation therapy (RT) is one of the mainstays of modern clinical cancer management. However, not all cancer types are equally sensitive to irradiation, often (but not always) because of differences...
6.
Stephan C, Demaria S, Hoda S
Am J Clin Pathol
. 2024 Mar;
162(2):211-212.
PMID: 38538079
No abstract available.
7.
Newman L, Chen Y, Martini R, Demaria S, Formenti S, Elemento O, et al.
JAMA Surg
. 2024 Mar;
159(6):712-714.
PMID: 38446467
No abstract available.
8.
Jahangir C, Page D, Broeckx G, Gonzalez C, Burke C, Murphy C, et al.
J Pathol
. 2024 Jan;
262(3):271-288.
PMID: 38230434
Recent advances in the field of immuno-oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in...
9.
Wisdom A, Barker C, Chang J, Demaria S, Formenti S, Grassberger C, et al.
Int J Radiat Oncol Biol Phys
. 2024 Jan;
118(5):1404-1421.
PMID: 38184173
Immunotherapeutic agents have revolutionized cancer treatment over the past decade. However, most patients fail to respond to immunotherapy alone. A growing body of preclinical studies highlights the potential for synergy...
10.
Lhuillier C, Van Nest S, Rudqvist N, Demaria S
Methods Cell Biol
. 2023 Oct;
180:25-37.
PMID: 37890930
Mutation-associated neoantigens are key targets of tumor-specific T cells and thus play a major role in driving responses to immune checkpoint blockade (ICB) therapy in tumors with high mutational burden....